SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Trinity Biotech plc (TRIB)

NEW YORK, Oct. 5, 2016

The investigation concerns whether Trinity and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On October 4, 2016, pre-market, Trinity revealed that it was withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer, following the U.S. Food and Drug Administration's advice. Trinity also said it would decrease its spending by roughly 85%, to $1.5 million from $9 million each year, and that it would close its Swedish facility, eliminating 40 jobs.  Following this news, Trinity stock dropped $6.53 per share, or 50.27%, to close at $6.46 on October 4, 2016.

If you are aware of any facts relating to this investigation, or purchased shares of Trinity, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/trib. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com